Literature DB >> 23266538

Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals.

Marie Kim Wium-Andersen1, David Dynnes Ørsted, Sune Fallgaard Nielsen, Børge Grønne Nordestgaard.   

Abstract

CONTEXT The pathogenesis of depression is not fully understood, but studies suggest that low-grade systemic inflammation contributes to the development of depression. OBJECTIVE To test whether elevated plasma levels of C-reactive protein (CRP) are associated with psychological distress and depression. DESIGN We performed cross-sectional and prospective analyses of CRP levels in 4 clinically relevant categories using data from 2 general population studies. SETTING The Copenhagen General Population and the Copenhagen City Heart studies. PARTICIPANTS We examined 73 131 men and women aged 20 to 100 years. MAIN OUTCOME MEASURES We ascertained psychological distress with 2 single-item self-reports and depression using self-reported antidepressant use, register-based prescription of antidepressants, and register-based hospitalization with depression. RESULTS In cross-sectional analyses, increasing CRP levels were associated with increasing risk for psychological distress and depression (P = 3 × 10-8 to P = 4 × 10-105 for trend). For self-reported use of antidepressants, the odds ratio was 1.38 (95% CI, 1.23-1.55) for CRP levels of 1.01 to 3.00 mg/L, 2.02 (1.77-2.30) for 3.01 to 10.00 mg/L, and 2.70 (2.25-3.25) for greater than 10.00 mg/L compared with 0.01 to 1.00 mg/L. For prescription of antidepressants, the corresponding odds ratios were 1.08 (95% CI, 0.99-1.17), 1.47 (1.33-1.62), and 1.77 (1.52-2.05), respectively; for hospitalization with depression, 1.30 (1.01-1.67), 1.84 (1.39-2.43), and 2.27 (1.54-3.32), respectively. In prospective analyses, increasing CRP levels were also associated with increasing risk for hospitalization with depression (P = 4 × 10-8 for trend). CONCLUSIONS Elevated levels of CRP are associated with increased risk for psychological distress and depression in the general population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23266538     DOI: 10.1001/2013.jamapsychiatry.102

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  141 in total

1.  Elevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective study.

Authors:  Marie Kim Wium-Andersen; David Dynnes Ørsted; Børge Grønne Nordestgaard
Journal:  Schizophr Bull       Date:  2013-08-31       Impact factor: 9.306

2.  Positive association between Toxoplasma gondii IgG serointensity and current dysphoria/hopelessness scores in the Old Order Amish: a preliminary study.

Authors:  Abhishek Wadhawan; Aline Dagdag; Allyson Duffy; Melanie L Daue; Kathy A Ryan; Lisa A Brenner; John W Stiller; Toni I Pollin; Maureen W Groer; Xuemei Huang; Christopher A Lowry; Braxton D Mitchell; Teodor T Postolache
Journal:  Pteridines       Date:  2017-11-22       Impact factor: 0.581

3.  Gene expression in major depressive disorder.

Authors:  R Jansen; B W J H Penninx; V Madar; K Xia; Y Milaneschi; J J Hottenga; A R Hammerschlag; A Beekman; N van der Wee; J H Smit; A I Brooks; J Tischfield; D Posthuma; R Schoevers; G van Grootheest; G Willemsen; E J de Geus; D I Boomsma; F A Wright; F Zou; W Sun; P F Sullivan
Journal:  Mol Psychiatry       Date:  2015-05-26       Impact factor: 15.992

4.  Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study.

Authors:  Manish K Jha; Abu Minhajuddin; Cherise Chin-Fatt; Tracy L Greer; Thomas J Carmody; Madhukar H Trivedi
Journal:  J Psychiatr Res       Date:  2019-03-20       Impact factor: 4.791

Review 5.  Do Statins Have Antidepressant Effects?

Authors:  Ole Köhler-Forsberg; Christiane Gasse; Michael Berk; Søren Dinesen Østergaard
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

6.  Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.

Authors:  Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Tracy Greer; Bruce Grannemann; Abigail Soyombo; Taryn L Mayes; A John Rush; Madhukar H Trivedi
Journal:  Psychoneuroendocrinology       Date:  2017-01-24       Impact factor: 4.905

7.  Five-factor model personality traits and inflammatory markers: new data and a meta-analysis.

Authors:  Martina Luchetti; James M Barkley; Yannick Stephan; Antonio Terracciano; Angelina R Sutin
Journal:  Psychoneuroendocrinology       Date:  2014-09-02       Impact factor: 4.905

8.  The relationship between antidepressant treatment and inflammatory markers in early psychosis: preliminary results.

Authors:  Alexander Stojanovic-Pérez; Lourdes Martorell; Itziar Montalvo; Laura Ortega; Montse Solé; Irene Moreno; Elisabet Vilella; Javier Labad
Journal:  Psychopharmacology (Berl)       Date:  2016-08-29       Impact factor: 4.530

Review 9.  From stress to inflammation and major depressive disorder: a social signal transduction theory of depression.

Authors:  George M Slavich; Michael R Irwin
Journal:  Psychol Bull       Date:  2014-01-13       Impact factor: 17.737

10.  Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk.

Authors:  Satish A Eraly; Caroline M Nievergelt; Adam X Maihofer; Donald A Barkauskas; Nilima Biswas; Agorastos Agorastos; Daniel T O'Connor; Dewleen G Baker
Journal:  JAMA Psychiatry       Date:  2014-04       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.